6YJP

Crystal structure of a complex between glycosylated NKp30 and its deglycosylated tumour ligand B7-H6


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.10 Å
  • R-Value Free: 0.322 
  • R-Value Work: 0.272 
  • R-Value Observed: 0.275 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Natural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its N -Glycosylation.

Skorepa, O.Pazicky, S.Kalouskova, B.Blaha, J.Abreu, C.Jecmen, T.Rosulek, M.Fish, A.Sedivy, A.Harlos, K.Dohnalek, J.Skalova, T.Vanek, O.

(2020) Cancers (Basel) 12

  • DOI: https://doi.org/10.3390/cancers12071998
  • Primary Citation of Related Structures:  
    6YJP

  • PubMed Abstract: 

    NKp30 is one of the main human natural killer (NK) cell activating receptors used in directed immunotherapy. The oligomerization of the NKp30 ligand binding domain depends on the length of the C-terminal stalk region, but our structural knowledge of NKp30 oligomerization and its role in signal transduction remains limited. Moreover, ligand binding of NKp30 is affected by the presence and type of N -glycosylation. In this study, we assessed whether NKp30 oligomerization depends on its N -glycosylation. Our results show that NKp30 forms oligomers when expressed in HEK293S GnTI - cell lines with simple N -glycans. However, NKp30 was detected only as monomers after enzymatic deglycosylation. Furthermore, we characterized the interaction between NKp30 and its best-studied cognate ligand, B7-H6, with respect to glycosylation and oligomerization, and we solved the crystal structure of this complex with glycosylated NKp30, revealing a new glycosylation-induced mode of NKp30 dimerization. Overall, this study provides new insights into the structural basis of NKp30 oligomerization and explains how the stalk region and glycosylation of NKp30 affect its ligand affinity. This furthers our understanding of the molecular mechanisms involved in NK cell activation, which is crucial for the successful design of novel NK cell-based targeted immunotherapeutics.


  • Organizational Affiliation

    Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, 12840 Prague, Czech Republic.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Natural cytotoxicity triggering receptor 3 ligand 1A [auth C],
B [auth D],
E
234Homo sapiensMutation(s): 1 
Gene Names: NCR3LG1B7H6
UniProt & NIH Common Fund Data Resources
Find proteins for Q68D85 (Homo sapiens)
Explore Q68D85 
Go to UniProtKB:  Q68D85
PHAROS:  Q68D85
GTEx:  ENSG00000188211 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ68D85
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChains Sequence LengthOrganismDetailsImage
Natural cytotoxicity triggering receptor 3C [auth A],
D [auth B]
126Homo sapiensMutation(s): 0 
Gene Names: NCR31C7LY117
UniProt & NIH Common Fund Data Resources
Find proteins for O14931 (Homo sapiens)
Explore O14931 
Go to UniProtKB:  O14931
PHAROS:  O14931
GTEx:  ENSG00000204475 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO14931
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

Unit Cell:
Length ( Å )Angle ( ˚ )
a = 166.044α = 90
b = 86.462β = 97.58
c = 111.299γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling
MoRDaphasing
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Czech Science FoundationCzech Republic18-10687S
Ministry of Education, Youth and Sports of the Czech RepublicCzech RepublicLTC17065
European Regional Development FundCzech RepublicCZ.02.1.01/0.0/0.0/16_013/0001776

Revision History  (Full details and data files)

  • Version 1.0: 2020-07-29
    Type: Initial release
  • Version 1.1: 2020-08-05
    Changes: Database references
  • Version 1.2: 2020-09-30
    Changes: Database references
  • Version 1.3: 2024-01-24
    Changes: Data collection, Database references, Refinement description